Õ¬Äи£Àû

Project Summary

Australia has looked on with concern at the widespread harm from prescription opioid painkillers in the US. Until recently, Australian use of prescription opioids such as oxycodone was increasing, and with it worries about addiction, overdose and other problems. Many people are prescribed these medicines after a visit to hospital and research in Australia and elsewhere has suggested that these individuals can go on to long-term and potentially problematic use. This project aims to generate robust and actionable information about the prevalence and natural history of prescription opioid use initiated during or soon after a hospital visit in Australia, focusing on persistent or long-term use and its harms.Ìý

Project date

Jun - Dec 2023

Investigators

Project Lead

Collaborators

Ìý- Õ¬Äи£Àû Sydney

Ms Ximena CamachoÌý- Õ¬Äи£Àû Sydney

Ms Kendal ChidwickÌý- Õ¬Äи£Àû Sydney

Ìý- University of Wollongong

Prof Louisa DegenhardtÌý- Õ¬Äи£Àû Sydney

A/Prof Natasa GisevÌý- Õ¬Äи£Àû Sydney

Prof Sallie PearsonÌý- Õ¬Äи£Àû Sydney

Research Question

What is the prevalence and natural history of opioid use initiated during hospital stay or post-discharge in New South Wales, particularly the prevalence of persistent opioid use?Ìý

Aims

1. Describe the proportion of people discharged from hospital/ED who were dispensed opioids soon after discharge, stratified by year and type of admissionÌý
2. Describe the proportion of people dispensed opioids post-discharge who subsequently used opioids persistently, stratified by year and type of admission

Data Sources

We will use population-based, linked administrative health data from the Medicines Intelligence Data Platform, comprising Pharmaceutical Benefit Scheme (PBS), Medicare Benefit Schedule (MBS), National Death Index (NDI)/Cause-of-death Unit Record File (CODURF), NSW Admitted Patient Data Collection (APDC), NSW Emergency Department Data Collection (EDDC), and NSW Clinical Cancer Registry (CCR) for all adult residents of NSW from 2002-2021.ÌýÌý

Policy Implications

Evidence from this study can help inform the type of interventions and their timing to reduce the risks associated with opioids initiated during hospital stay or at discharge

End Users

• clinicians
• regulators
• guidelines authors
• safety and quality professionals
• hospital drug and therapeutics committees

Impact

The research paper with results from our study appeared in theÌýÌýon 27 May 2024. The work has also been presented in several forums including theÌý2023 MI-CRE Annual Research SymposiumÌýand a National Drug and Alcohol Research CentreÌýÌýon 11 April 2024, with over 200 registered participants from the wider drug and alcohol community and an international panellist, Jay Gong from the University of Auckland. The research has also been accepted to present to an international audience at the International Society for Pharmacoepidemiology annual conference in Berlin in August 2024.

The research also generated stories in trade and general media, including The Courier Mail, PharmaDispatch, The Limbic and Australian Journal of Pharmacy.

The published paper will also be shared with our contacts at TGA, DUSC and ACSQHC to inform future policy in the area.